Available interim reports from some of the trials show promising objective response rates (ORR) for the treatment of ovarian cancer with nivolumab (anti-PD-1) (ORR of 15%, n = 20 patients), pembrolizumab (ORR 11.5%, n = 49), or avelumab (anti-PD-L1) (ORR 10%, n = 124) (17, 58, 59). This evidence concerns the gene CD274 and ovarian carcinoma.